FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond

• Published in: The oncologist (Dayton, Ohio) Vol. 22; no. 11; pp. 1392 - 1399
• Main Authors: Pai‐Scherf, Lee, Blumenthal, Gideon M., Li, Hongshan, Subramaniam, Sriram, Mishra‐Kalyani, Pallavi S., He, Kun, Zhao, Hong, Yu, Jingyu, Paciga, Mark, Goldberg, Kirsten B., McKee, Amy E., Keegan, Patricia, Pazdur, Richard
• Format: Journal Article
• Language: English
• Published: United States AlphaMed Press 01.11.2017
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; B7-H1 Antigen - genetics; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Disease Progression; Drug Approval; EGFR protein, Human; Gene Expression Regulation, Neoplastic - drug effects; Humans; Middle Aged; Non‐small cell lung cancer; Pembrolizumab; Receptor, Epidermal Growth Factor - genetics; Regulatory Issues: FDA; Taxoids - administration & dosage; United States; United States Food and Drug Administration; Pembrolizumab; EGFR protein, Human; Non‐small cell lung cancer; United States Food and Drug Administration

On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non‐small cell lung cancer (mNSCLC) whose tumors express programmed death‐ligand 1 (PD‐L1) as determined by an FD...